[Association between gene polymorphisms of Perforin 1 and hemophagocytic lymphohistiocytosis]

Xiao-Hua Huang1, Jian-Ming Luo, Qiong Bin

  • 1Department of Pediatrics, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China. jmluo@aliyun.com.

Insights

This study found no link between PRF1 gene polymorphisms and hemophagocytic lymphohistiocytosis (HLH) susceptibility in children. The PRF1 gene variations investigated do not appear to increase the risk of developing HLH.

Area of Science:

  • Genetics
  • Immunology
  • Pediatrics

Context:

  • Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome.
  • Genetic factors are implicated in HLH pathogenesis, but specific gene associations require further investigation.
  • The PRF1 gene encodes perforin, a key molecule in cytotoxic T lymphocyte and natural killer cell function, making it a candidate for HLH association studies.

Purpose:

  • To determine the frequency distribution of PRF1 gene polymorphisms in children diagnosed with HLH.
  • To investigate whether specific PRF1 gene polymorphisms are associated with an increased risk of susceptibility to HLH in a pediatric cohort.

Summary:

  • The study genotyped the PRF1 gene in 48 children with HLH and 100 healthy controls using PCR and direct sequencing.
  • Three single nucleotide polymorphisms (SNPs) were found in the coding region and seven in the noncoding region of PRF1.
  • No significant differences in allelic frequencies or A-T haplotype distribution were observed between the HLH and control groups, indicating no association between PRF1 polymorphisms and HLH susceptibility.

Impact:

  • This research suggests that common PRF1 gene polymorphisms are not a significant risk factor for developing HLH in the studied pediatric population.
  • The findings contribute to understanding the genetic landscape of HLH, potentially guiding future research towards other genetic contributors.
  • While a linkage disequilibrium was noted between rs10999426 and rs10999427, their low detection rate in healthy children suggests they do not confer a protective effect against HLH.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
19.8K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
135
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.3K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.7K